Orthocell Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Orthocell.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	16.1%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Oct 25

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

May 31

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Feb 15

How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?

Dec 24

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Orthocell no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

ASX:OCC - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2023	5	-7	-7	-7	N/A
9/30/2023	5	-7	3	4	N/A
6/30/2023	4	-6	14	15	N/A
3/31/2023	3	-7	14	14	N/A
12/31/2022	2	-9	13	14	N/A
9/30/2022	2	-9	3	4	N/A
6/30/2022	2	-9	-7	-6	N/A
3/31/2022	1	-9	-6	-6	N/A
12/31/2021	1	-9	-6	-6	N/A
9/30/2021	1	-9	-5	-5	N/A
6/30/2021	1	-9	-5	-5	N/A
3/31/2021	1	-9	-4	-4	N/A
12/31/2020	1	-8	-4	-4	N/A
9/30/2020	1	-7	-5	-5	N/A
6/30/2020	1	-6	-5	-5	N/A
3/31/2020	1	-6	-7	-6	N/A
12/31/2019	1	-7	-8	-8	N/A
9/30/2019	1	-6	-6	-6	N/A
6/30/2019	1	-6	-5	-4	N/A
3/31/2019	1	-6	-5	-4	N/A
12/31/2018	1	-6	-5	-4	N/A
9/30/2018	1	-6	-5	-4	N/A
6/30/2018	1	-6	-5	-5	N/A
3/31/2018	1	-4	-4	-3	N/A
12/31/2017	1	-2	-2	-2	N/A
9/30/2017	1	-3	N/A	-3	N/A
6/30/2017	1	-4	N/A	-4	N/A
3/31/2017	1	-4	N/A	-4	N/A
12/31/2016	1	-4	N/A	-4	N/A
9/30/2016	1	-4	N/A	-4	N/A
6/30/2016	1	-4	N/A	-3	N/A
3/31/2016	1	-4	N/A	-3	N/A
12/31/2015	1	-3	N/A	-3	N/A
9/30/2015	1	-4	N/A	-3	N/A
6/30/2015	1	-4	N/A	-3	N/A
3/31/2015	1	-4	N/A	-3	N/A
12/31/2014	1	-5	N/A	-4	N/A
9/30/2014	1	-3	N/A	-3	N/A
6/30/2014	1	-2	N/A	-2	N/A
3/31/2014	1	-2	N/A	-1	N/A
12/31/2013	1	-1	N/A	0	N/A
9/30/2013	1	-1	N/A	0	N/A
6/30/2013	1	-1	N/A	0	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de OCC es superior a la tasa de ahorro (2.2%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de OCC crezcan más rápidamente que el mercado Australian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de OCC crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de OCC crezcan más rápidamente que el mercado de Australian.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de OCC crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de OCC se prevé que sea elevada dentro de 3 años.

Orthocell Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023

Recent updates

Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 3.500001 million.

New minor risk - Shareholder dilution

Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.

Orthocell Limited Announces Resignation of Matthew Callahan from the Board

Orthocell Limited Announces Changes to its Board

Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Orthocell Limited Announces Board Changes

Less than half of directors are independent

Orthocell Limited Announces Board Changes

Orthocell Limited, Annual General Meeting, Oct 31, 2023

Full year 2023 earnings released: AU$0.032 loss per share (vs AU$0.047 loss in FY 2022)

New minor risk - Financial data availability

Orthocell Limited Appoints John Van Der Wielen as Independent Non-Executive Chairman, Effective 1 June 2023

First half 2023 earnings released: AU$0.021 loss per share (vs AU$0.024 loss in 1H 2022)

We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth

Less than half of directors are independent

Orthocell Limited's Rotator Cuff Study Success with Cross-Over Patients

Orthocell Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: AU$0.047 loss per share (vs AU$0.048 loss in FY 2021)

We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate

Orthocell Limited Announces the Completion of Its RemplirTM Nerve Reconstruction Study

Less than half of directors are independent

Orthocell (ASX:OCC) Is In A Good Position To Deliver On Growth Plans

Orthocell Ordinary Shares to Be Deleted from Other OTC

We're Not Worried About Orthocell's (ASX:OCC) Cash Burn

CEO, MD & Executive Director recently sold AU$552k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2021 earnings released: AU$0.047 loss per share (vs AU$0.036 loss in FY 2020)

Orthocell Limited Announces CelGro Nerve Study Results

Orthocell Limited Announces First Interim Data Read Out of All Patients in the Celgro® Nerve Regeneration Trial At 12 Months Post Treatment

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

Orthocell Limited Announces New Collagen Rope Patent for CelGro Platform Technology

Celgro Study Results Open Up New US Market Access Strategy

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Orthocell Limited Announces Publication of Successful Case Study Focussing on the Combination of Celgro® Collagen Medical Device and Autologous Tenocyte Implantation for the Surgical Repair of Large Degenerate Tear of the Gluteal Medius Tendo

Orthocell Ltd Receives US Market Clearance

Orthocell Limited Receives First US CelGro Product Approval

New 90-day high: AU$0.49

Orthocell Limited Receives Australian Market Approval for its Celgro, a Collagen Medical Device

How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?

New 90-day high: AU$0.46

Orthocell Limited Announces Patient Enrolment for the Celgro® Nerve Regeneration Trial Is Now Complete

New 90-day low: AU$0.33

Orthocell Limited Announces CelGro Bone Regeneration in Dental & Orthopedic Applications

Full year earnings released - AU$0.036 loss per share

New 90-day high - AU$0.43

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento